TuHURA Biosciences Inc Dossier
Qualitative Analysis
Business overview
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy. The company's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors by utilizing plasmid DNA to encode a bacterial protein (Emm55) on cancer cells, thereby triggering a robust systemic immune response. Additionally, TuHURA is advancing TBS-2025, a novel VISTA-inhibiting monoclonal antibody acquired through its merger with Kineta, Inc. in June 2025, which targets myeloid-derived suppressor cells (MDSCs) and is moving into clinical trials for blood-related cancers.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead innate immune agonist candidate, IFx-2.0, in a single randomized, placebo-controlled Phase 3 registration trial as an adjunctive therapy to Keytruda (pembrolizumab) for first-line treatment of advanced or metastatic Merkel Cell Carcinoma (MCC).
Expected impact: Aims to overcome primary resistance to checkpoint inhibitors and achieve accelerated FDA approval based on Overall Response Rate (ORR).
Developing TBS-2025, a novel V-domain Ig suppressor of T-cell activation (VISTA)-inhibiting monoclonal antibody, for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.
Expected impact: Aims to address acquired resistance to immunotherapies in patients with mutNPM1 relapsed/refractory AML, initially as a monotherapy (Phase 1b) and subsequently in combination with menin inhibitors (Phase 2).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire the rights to the novel VISTA-inhibiting monoclonal antibody KVA12123 (renamed TBS-2025), expanding TuHURA's clinical pipeline with a Phase 2-ready asset targeting acquired resistance in hematologic and solid tumors.
Financial impact: The transaction was structured as a merger involving cash and stock. It unlocked additional PIPE financing tranches and added significant R&D assets, accompanied by non-cash in-process R&D write-offs.
Strategic Partnerships
Evaluating TuHURA's lead candidate IFx-2.0 as an adjunctive therapy administered alongside Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in the pivotal Phase 3 registration trial for Merkel Cell Carcinoma.
Terms: Not explicitly disclosed.